---
type: "NewsArticle"
title: "SUPPLX recalls two products after undeclared yohimbine finding"
description: "SUPPLX voluntarily recalled Business Pill and Branch Manager for Men after testing identified undeclared yohimbine; FDA posted the notice on September 4."
resource: "https://nootropikler.com/news/fda-recalls-products-undeclared-yohimbine"
tags: ["brain-health", "evidence-limits", "safety"]
timestamp: 2026-10-04T23:57:49Z
language: "en"
---

# SUPPLX recalls two products after undeclared yohimbine finding

SUPPLX voluntarily recalled Business Pill and Branch Manager for Men after testing identified undeclared yohimbine; FDA posted the notice on September 4.

Author: Nootropik News Editorial Team
Published: 2026-10-04T23:57:49Z
Update: 2026-10-04T23:57:49Z
News/source date: 2026-09-04
Production: AI-assisted sourced summary and translation; no independent medical expert review is claimed.

## What happened

FDA posted a SUPPLX voluntary recall notice on September 4, 2026, following the company’s September 3 announcement. Testing identified undeclared yohimbine in Business Pill and Branch Manager for Men, with the notice describing dangerously high levels. The recall covered all lots and expiration dates of those two products distributed from September 16, 2023 through June 11, 2026. It did not cover every SUPPLX product or constitute a new clinical trial of yohimbine.

## Why it matters

An undeclared pharmacologically active ingredient prevents buyers from assessing what they are taking. The notice warned that yohimbine can affect heart rate and blood pressure and may interact with other medicines or stimulants. This makes the finding relevant to products sold with performance-oriented positioning, even though the recall did not establish any cognitive benefit. Ingredient transparency and measured composition are separate requirements from a claim that a product supports focus or energy.

## Scope and limitations

The company instructed consumers to stop using and dispose of the recalled products and to contact a healthcare provider about related adverse effects. The official notice supplies the product identifiers and consumer contact information. This article does not estimate an unreported injury count, infer that every product containing declared yohimbine has the same risk, or establish sales in Turkey. FDA’s publication of a company announcement is also not an endorsement of that company’s products. The scope is the named products and recall period.

## Sources

- [SUPPLX.com recall of Business Pill and Branch Manager for Men](https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/supplxcom-issues-voluntary-nationwide-recall-business-pill-and-branch-manager-men-due-undeclared) — 2026-09-04
